Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Entrada Therapeutics (TRDA) Non Operating Income (2022 - 2025)

Entrada Therapeutics has reported Non Operating Income over the past 4 years, most recently at $3.1 million for Q4 2025.

  • Quarterly results put Non Operating Income at $3.1 million for Q4 2025, down 38.85% from a year ago — trailing twelve months through Dec 2025 was $15.1 million (down 22.6% YoY), and the annual figure for FY2025 was $15.1 million, down 22.6%.
  • Non Operating Income for Q4 2025 was $3.1 million at Entrada Therapeutics, down from $3.6 million in the prior quarter.
  • Over the last five years, Non Operating Income for TRDA hit a ceiling of $5.8 million in Q3 2024 and a floor of $403000.0 in Q2 2022.
  • Median Non Operating Income over the past 4 years was $4.0 million (2023), compared with a mean of $3.3 million.
  • Biggest five-year swings in Non Operating Income: surged 946.65% in 2023 and later crashed 38.85% in 2025.
  • Entrada Therapeutics' Non Operating Income stood at $950000.0 in 2022, then surged by 351.79% to $4.3 million in 2023, then rose by 19.48% to $5.1 million in 2024, then crashed by 38.85% to $3.1 million in 2025.
  • The last three reported values for Non Operating Income were $3.1 million (Q4 2025), $3.6 million (Q3 2025), and $3.9 million (Q2 2025) per Business Quant data.